1. Home
  2. VYGR vs QTRX Comparison

VYGR vs QTRX Comparison

Compare VYGR & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • QTRX
  • Stock Information
  • Founded
  • VYGR 2013
  • QTRX 2007
  • Country
  • VYGR United States
  • QTRX United States
  • Employees
  • VYGR N/A
  • QTRX N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • QTRX Biotechnology: Laboratory Analytical Instruments
  • Sector
  • VYGR Health Care
  • QTRX Industrials
  • Exchange
  • VYGR Nasdaq
  • QTRX Nasdaq
  • Market Cap
  • VYGR 191.9M
  • QTRX 223.6M
  • IPO Year
  • VYGR 2015
  • QTRX 2017
  • Fundamental
  • Price
  • VYGR $3.17
  • QTRX $5.28
  • Analyst Decision
  • VYGR Strong Buy
  • QTRX Buy
  • Analyst Count
  • VYGR 9
  • QTRX 5
  • Target Price
  • VYGR $14.86
  • QTRX $16.20
  • AVG Volume (30 Days)
  • VYGR 282.0K
  • QTRX 603.8K
  • Earning Date
  • VYGR 05-06-2025
  • QTRX 05-12-2025
  • Dividend Yield
  • VYGR N/A
  • QTRX N/A
  • EPS Growth
  • VYGR N/A
  • QTRX N/A
  • EPS
  • VYGR N/A
  • QTRX N/A
  • Revenue
  • VYGR $66,958,000.00
  • QTRX $137,421,000.00
  • Revenue This Year
  • VYGR N/A
  • QTRX $5.22
  • Revenue Next Year
  • VYGR $2.04
  • QTRX $15.31
  • P/E Ratio
  • VYGR N/A
  • QTRX N/A
  • Revenue Growth
  • VYGR N/A
  • QTRX 12.30
  • 52 Week Low
  • VYGR $2.75
  • QTRX $4.67
  • 52 Week High
  • VYGR $9.55
  • QTRX $19.18
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 40.49
  • QTRX 41.90
  • Support Level
  • VYGR $3.46
  • QTRX $5.21
  • Resistance Level
  • VYGR $3.69
  • QTRX $5.75
  • Average True Range (ATR)
  • VYGR 0.18
  • QTRX 0.41
  • MACD
  • VYGR 0.00
  • QTRX 0.04
  • Stochastic Oscillator
  • VYGR 0.00
  • QTRX 21.09

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About QTRX Quanterix Corporation

Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.

Share on Social Networks: